Joseph Harold Friedman

Joseph Harold Friedman's AcademicInfluence.com Rankings

Biology

#9258

Historical Rank

Neuroscience

#821

Historical Rank

biology Degrees

Download Badge

Biology

Joseph Harold Friedman's Degrees

PhD Neuroscience Stanford University

Why Is Joseph Harold Friedman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joseph Harold Friedman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. (1993) (1186)
A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (2016) (1125)
Effect of deprenyl on the progression of disability in early Parkinson's disease. (1989) (886)
Fatigue in Parkinson's disease: A review (2007) (322)
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014) (294)
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease (1997) (290)
Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis (2010) (238)
Orienting of visual attention in progressive supranuclear palsy. (1988) (229)
Neuropsychiatric symptoms in Parkinson's disease (2011) (225)
Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease (2000) (223)
Spinal Cord Infarction: Report of 8 Cases and Review of the Literature (1989) (221)
Longitudinal outcome of Parkinson’s disease patients with psychosis (2003) (219)
Effects of fatigue on physical activity and function in patients with Parkinson’s disease (2003) (215)
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. (2014) (205)
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease (2010) (203)
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease (2002) (186)
Political Correctness. (2017) (180)
A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. (1985) (169)
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. (1995) (165)
Scales to assess psychosis in Parkinson's disease: Critique and recommendations (2008) (158)
Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. (2013) (145)
Gait in the elderly. (2008) (143)
Fatigue in levodopa-naïve subjects with Parkinson disease (2008) (140)
The emergin role of clozapine in the treatment of movement disorders (1997) (136)
'It's complicated'. (2014) (131)
Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. (2001) (125)
Long‐term outcome of quetiapine use for psychosis among parkinsonian patients (2003) (125)
Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease (2006) (123)
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. (2010) (123)
Punding on L‐dopa (1999) (116)
Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience (2004) (115)
Clozapine in the treatment of psychosis in Parkinson's disease (1989) (114)
Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. (1999) (113)
The placebo response in Parkinson's disease. Parkinson Study Group. (1999) (109)
Crimes against humanity. (2017) (106)
Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. (2002) (106)
Does fluoxetine exacerbate Parkinson's disease? (1992) (104)
Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients (2004) (104)
Ophthalmologic features of Parkinson's disease. (2004) (101)
Mood and sleep in Parkinson's disease. (2006) (101)
Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial (2001) (101)
Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients (1998) (99)
Respiratory muscle dysfunction in Parkinson's disease. (1988) (97)
What is a disease? (2017) (96)
Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. (2007) (94)
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
Programming and execution of sequential movements in Parkinson's disease. (1987) (91)
Parkinson's disease psychosis 2010: a review article. (2010) (90)
Punding on levodopa (1994) (89)
The management of the levodopa psychoses. (1991) (88)
Benztropine versus clozapine for the treatment of tremor in Parkinson's disease (1997) (88)
Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm (2018) (88)
Quetiapine for the treatment of drug‐induced psychosis in Parkinson's disease (1999) (87)
CLASSIFICATION AND TREATMENT OF TARDIVE SYNDROMES (2003) (85)
Sleep and fatigue in Parkinson's disease. (2004) (85)
Parkinson Disease Psychosis: Update (2013) (84)
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. (2014) (83)
Prevalence, Clinical Characteristics, and Pharmacologic Treatment of Parkinson's Disease in Residents in Long‐Term Care Facilities (1999) (83)
Parkinson's disease‐related fatigue: A case definition and recommendations for clinical research (2016) (81)
Executive and emotional dysfunction in Machado‐Joseph disease (2002) (81)
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. (2011) (80)
Reduction of freezing of gait in Parkinson's disease by repetitive robot-assisted treadmill training: a pilot study (2010) (80)
Nonmotor Symptoms in Parkinson's Disease (2017) (79)
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. (2010) (78)
Gamma knife pallidotomy in advanced parkinson's disease (1996) (77)
Phenomenology of dreams in Parkinson's disease (2007) (76)
Drug-Induced Psychosis in Parkinson Disease: Phenomenology and Correlations Among Psychosis Rating Instruments (2005) (74)
REM behavior disorder and excessive daytime somnolence in Machado–Joseph disease (SCA‐3) (2003) (72)
Rating scales. (2013) (71)
Respiration and sleep in Parkinson's disease. (1986) (70)
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. (2011) (69)
Mission statements. (2008) (67)
Physical Activity and Neuropsychiatric Symptoms of Parkinson Disease (2012) (65)
A comparison of fatigue measures in Parkinson's disease. (2007) (65)
PRACTICE PARAMETER: ASSESSING PATIENTS IN A NEUROLOGY PRACTICE FOR RISK OF FALLS (AN EVIDENCE-BASED REVIEW): REPORT OF THE QUALITY STANDARDS SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY (2009) (65)
Predictors of depressive symptoms among spouse caregivers in Parkinson's disease (2001) (62)
Tardive dystonia in a psychiatric hospital. (1987) (62)
Incidence and mortality trends of aspiration pneumonia in Parkinson's disease in the United States, 1979-2010. (2015) (60)
Fatigue in Parkinson’s disease: report from a mutidisciplinary symposium (2016) (60)
Treatment of Psychosis in Parkinson’s Disease (2001) (59)
Donepezil for Huntington's disease (2000) (58)
Anxiety and Depression in Parkinson’s Disease (2014) (57)
Falls and the falls efficacy scale in Parkinson’s disease (2010) (57)
Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. (2002) (56)
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. (2009) (56)
Monozygotic twins discordant for Huntington disease after 7 years. (2005) (55)
Myoclonic dystonia (2004) (55)
Atypical Antipsychotics in Parkinson-Sensitive Populations (2002) (54)
Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. (1998) (54)
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease (2010) (53)
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease (2008) (51)
Long‐term outcome of clozapine use for psychosis in parkinsonian patients (2004) (50)
Gender differences in the frequency and treatment of behavior problems in Parkinson's disease (2000) (50)
Olfaction in Parkin heterozygotes and compound heterozygotes (2010) (49)
Testosterone deficiency and apathy in Parkinson’s disease: a pilot study (2004) (48)
Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. (1987) (48)
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up (2001) (47)
Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases (1994) (47)
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial (2014) (46)
Preparation of manual movements in hemiparkinsonism. (1989) (44)
Crack cocaine use due to dopamine agonist therapy in Parkinson disease (2013) (44)
Recent developments in drug-induced movement disorders: a mixed picture (2019) (43)
Rapid diagnosis. (2015) (42)
Sleep symptoms and their clinical correlates in Machado–Joseph disease (2009) (41)
Limb dystonia in progressive supranuclear palsy (1987) (41)
Current Use of Clozapine in Parkinson Disease and Related Disorders (2010) (41)
Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects (2010) (41)
Psychogenic disorders: the need to speak plainly. (2010) (41)
Olfaction and apathy in Parkinson's disease. (2010) (40)
Dementia with Lewy Bodies and Parkinson Disease Dementia: It is the Same Disease! (2018) (40)
A survey of Parkinson's disease patients: most bothersome symptoms and coping preferences. (2014) (39)
Idiopathic hypoparathyroidism with extensive brain calcification and persistent neurologic dysfunction (1987) (38)
Late onset of distinct neurologic syndromes in galactosemic siblings (1989) (38)
The Role of Atypical Antipsychotics in the Treatment of Movement Disorders (1999) (37)
Atypical antipsychotics in the EPS-vulnerable patient (2003) (36)
The relation between depression and parkin genotype: the CORE-PD study. (2011) (36)
Non-Motor Aspects of Parkinson's Disease (2006) (36)
Hypotension due to glossopharyngeal neuralgia. (1986) (36)
Apathy in Neurodegenerative Diseases (2015) (35)
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. (1994) (35)
Global aphasia in multiple sclerosis (1983) (35)
Sleep Disturbances and Parkinson's Disease (2008) (34)
Risperidone and parkinson's disease (2002) (34)
Cognitive behavioral therapy for psychogenic movement disorder (2009) (34)
Attention-Deficit and Disruptive Behavior Disorders (2014) (33)
Motor asymmetry over time in Parkinson’s disease (2018) (33)
Botulinum toxin type B for gait freezing in Parkinson's disease. (2004) (30)
Experience with DaTscan at a tertiary referral center. (2015) (30)
Parkinsonism in a Nursing Home: Underrecognition (2004) (29)
'Drug holidays' in the treatment of Parkinson's disease. A brief review. (1985) (29)
“Rubral” tremor induced by a neuroleptic drug (1992) (29)
Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. (2007) (28)
Yawning as an aura for an L-dopa-induced "on" in Parkinson's disease (1998) (28)
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications (2018) (28)
It's all in your head. (2004) (28)
Atypical antipsychotic use and risk of fracture in persons with Parkinsonism (2009) (28)
Testosterone not associated with violent dreams or REM sleep behavior disorder in men with Parkinson's (2007) (28)
Dystonia in Machado-Joseph disease: Clinical profile, therapy and anatomical basis. (2015) (27)
Fatigue in Parkinson’s disease patients (2009) (27)
Diabetes mellitus among parkinsonian patients treated chronically with clozapine. (2004) (27)
Atypical Antipsychotic Drugs in the Treatment of Parkinson’s Disease (2011) (27)
CACNA1A Mutation in a EA-2 Patient Responsive to Acetazolamide and Valproic Acid (2006) (26)
Repetitive and impulsive behaviors in treated Parkinson disease (2006) (25)
Historical perspective on movement disorders. (2004) (25)
Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. SAGE Study Group. Systematic Assessment and Geriatric drug use via Epidemiology. (2000) (25)
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study (2010) (25)
The association between fatigue and apathy in patients with either Parkinson's disease or multiple sclerosis. (2015) (24)
Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3 (2020) (23)
Inflammation and fatigue in early, untreated Parkinson's Disease (2018) (22)
Machado‐joseph disease/spinocerebellar ataxia 3 responsive to buspirone (1997) (22)
THE NONMOTOR PROBLEMS OF PARKINSON'S DISEASE (2000) (22)
Levodopa addiction in idiopathic Parkinson disease (2005) (22)
Treating psychosis in movement disorder patients: a review (2014) (22)
Progressive parkinsonism in boxers. (1989) (22)
Atypical antipsychotics in the elderly with Parkinson disease and the “black box” warning (2006) (21)
The management of psychosis in movement disorder patients (2007) (21)
Non‐movement disorder heralds symptoms of Machado‐Joseph disease years before ataxia (2005) (21)
The contribution of apathy and increased learning trials to risky decision-making in Parkinson's disease. (2014) (21)
Neuroleptic malignant syndrome. The results of a 6-month prospective study of incidence in a state psychiatric hospital. (1988) (21)
Fatigue in Parkinson's disease (2011) (21)
Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? (2001) (20)
Fatigue and daytime somnolence in Machado Joseph Disease (spinocerebellar ataxia type 3) (2008) (20)
Suggestive linkage of chromosome 10p to schizophrenia is not due to transmission ratio distortion. (1999) (20)
Letter to the Editor: Successful Use of Electroconvulsive Therapy for Refractory Anxiety in Parkinson's Disease (2012) (19)
Melperone is ineffective in treating Parkinson's disease psychosis (2012) (19)
SPG11‐related parkinsonism: Clinical profile, molecular imaging and l‐dopa response (2018) (19)
A case of senile chorea (1990) (19)
Hemi‐parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging (2001) (18)
Associations between Severity of Motor Function and Nonmotor Symptoms in Parkinson's Disease: A Post Hoc Analysis of the RECOVER Study (2014) (18)
Pharmacological interventions for psychosis in Parkinson’s disease patients (2018) (18)
The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study (2015) (17)
Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson's disease. (2001) (17)
Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials (2015) (17)
Best medical schools. (2009) (17)
Parkinson's disease update. (1989) (16)
Ataxia without telangiectasia (1993) (16)
Syndrome of diffuse encephalopathy due to nondominant thalamic infarction (1985) (16)
Analogies (1921) (15)
Pimavanserin for the treatment of Parkinson's disease psychosis (2013) (15)
Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease (2015) (15)
Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman (2001) (15)
Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2019) (15)
Conversion disorder (2010) (15)
Electroconvulsive Therapy in Parkinson's Disease: A Report on Five Cases. (1992) (15)
Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient. (2010) (15)
PLA2G6 mutations and Parkinsonism: Long‐term follow‐up of clinical features and neuropathology (2016) (15)
Misperceptions and Parkinson's disease (2017) (15)
Weight problems and psychological factors. (1959) (15)
Re: Atypical Antipsychotics Mechanisms of Action (2003) (14)
Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia. (2017) (14)
Ice cream preference in Parkinson's disease. (2010) (14)
A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic (2017) (14)
Unrecognized parkinsonism in acute care medical patients receiving neurological consultations. (2003) (14)
Viewpoint: challenges in our understanding of neuroleptic induced parkinsonism. (2014) (14)
Tardive Dyskinesia‐like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non‐existent: Literature Review (2018) (13)
Self perceived weakness in Parkinson's disease. (2012) (13)
A family with a tau P301L mutation presenting with parkinsonism. (2002) (13)
Stroke induced by gamma knife pallidotomy: autopsy result. (2002) (13)
Rhinorrhea is increased in Parkinson's disease (2008) (12)
RHINORRHEA AND OLFACTION IN PARKINSON DISEASE (2008) (12)
Drug-induced parkinsonism in the elderly (2007) (12)
Feasibility of use of probabilistic reversal learning and serial reaction time tasks in clinical trials of Parkinson's disease. (2015) (12)
An investigation of the coexistence of abnormal involuntary movements, parkinsonism, and akathisia in chronic psychiatric inpatients. (1987) (11)
Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2019) (11)
Enteric Pathologic Manifestations of Alpha-Synucleinopathies (2017) (11)
Systematic review of caudal epidural injections in the management of chronic back pain. (2013) (11)
Gold standards. (2009) (10)
Progressive parkinsonism associated with Rosenthal fibers (1992) (10)
Neuropsychiatric Symptoms in an Inpatient Parkinson's Disease Sample (2014) (10)
Hiccups and vomiting as initial manifestations of multiple sclerosis. (1987) (10)
Quetiapine for Parkinson's Disease psychosis: Evidence‐based medicine versus expert belief: A case study (2018) (10)
Is Urinary Incontinence Different in Women with Parkinson’s Disease? (1999) (9)
Internal tremor in Parkinson's disease, multiple sclerosis, and essential tremor. (2015) (9)
Movement disorders induced by psychiatric drugs that do not block dopamine receptors. (2020) (9)
Managing idiopathic Parkinson's disease in patients with schizophrenic disorders. (2011) (8)
Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review (2018) (8)
No brainer. (2000) (8)
Ageism in Health Care? (2015) (8)
Cervical stenosis and dystonic cerebral palsy (1999) (8)
Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours (2011) (8)
Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review (2018) (8)
More on repetitive behaviors in Parkinson's disease (2005) (8)
Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases (2005) (8)
Young‐onset Parkinson's disease: A clinical pathologic description of two siblings (2000) (8)
Valbenazine-induced parkinsonism. (2019) (7)
Progressive myalgias and polyarthralgias in a patient with myoadenylate deaminase deficiency. (1985) (7)
Glad about SAD (PD) (2012) (7)
Walking‐induced parkinsonism due to presumed idiopathic normal pressure hydrocephalus (1996) (7)
Akathisia with clozapine (1993) (7)
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease. (1989) (7)
Dementia, ataxia and parkinsonism associated with the antiphospholipid syndrome. (2011) (6)
Reducing risk factors. (2011) (6)
Rapid resolution of organic mental syndrome in sickle cell anemia in response to exchange transfusion (1981) (6)
Akathisia: the syndrome of motor restlessness. (1987) (6)
Psychiatry for neurologists (2006) (6)
Multiple re-challenges for clozapine neutropenia in Parkinson's disease. (2016) (6)
Tardive syndromes in the elderly. (2006) (6)
Spinal surgery for severe scoliosis in Parkinson's disease. (2000) (6)
Enhanced fatigue during motor performance in patients with PD. (1999) (6)
Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient. (2017) (6)
Behavioral dysfunction in Parkinson's disease. (1998) (6)
Atypical antipsychotics have very different adverse effect profiles and should not be lumped together. (2006) (5)
Editorial on: Pagonabarraga J, Martinez‐Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug‐naïve Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432 (2016) (5)
Hemifacial gustatory sweating due to Pancoast's tumor. (1987) (5)
Long-term outcomes with pimavanserin for psychosis in clinical practice (2022) (5)
Psychosis in Parkinson’s disease: unexplained observations in a seemingly simple model (2016) (5)
Involuntary humming in autopsy-proven Parkinson's disease. (1993) (5)
A case of progressive hemichorea responsive to high-dose reserpine. (1986) (5)
A-31The Effects of Rasagiline on Cognition in Mild to Moderate Stage Parkinson's Disease, A Double-Blind Placebo Controlled Study (2014) (5)
Rating instruments. (2008) (5)
Symptoms of neuroleptic malignant syndrome. (1987) (5)
Surgical treatment for Parkinson’s disease (2012) (5)
Advances in neurology, volume 49 (facial dyskinesias). Joseph Jankovic, Edwardo Tolosca, (eds), Raven press, New York, $102.00. 1988 (1989) (5)
Efficacy and tolerability of NUPLAZID™ (pimavanserin) in PD Psychosis: Analysis of an integrated Phase 3 placebo-controlled dataset (2016) (5)
Ophthalmologic features of Parkinson's disease. Authors' reply (2004) (4)
Expert opinions. (2018) (4)
Is fatigue in early Parkinson’s disease a minor inconvenience or major distress? The answer is ‘yes!’ (2012) (4)
Rostral basilar reversible ischemic neurologic deficit in an HIV-infected patient with cryptococcal meningitis. (1990) (4)
Corrigendum: Fatigue in Parkinson’s disease: report from a multidisciplinary symposium (2017) (4)
Shunting for normal pressure hydrocephalus in patients with neurodegenerative disorders (2013) (4)
New-Onset Diabetes Mellitus among Parkinsonian Patients Treated with Long-term Quetiapine (2008) (4)
Medical Tourism. (2016) (4)
Perioperative management of Parkinson’s disease (2017) (4)
Should risperidone be used in Parkinson's disease? (1998) (4)
The placebo effect (2008) (4)
Intravenous levodopa in hallucinating PD patients. (1999) (4)
Thalamic infarct and diffuse encephalopathy (1986) (4)
Mood, Emotion, and Thought (2007) (4)
Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3 (2021) (4)
Treatment of Parkinson’s Disease Psychosis (2019) (4)
Acute Parkinsonism (2017) (4)
Catatonia responsive to lorazepam: A case report (1999) (3)
The Glabellar reflex is a poor measure of Parkinson motor severity (2013) (3)
The physical exam. (2014) (3)
Clozapine and the mandatory monitoring system. (1991) (3)
Effects of Vestibular Rehabilitation on Fatigue and Activities of Daily Living in People with Parkinson's Disease: A Pilot Randomized Controlled Trial Study (2020) (3)
Tardive Syndromes. (2019) (3)
Idiopathic normal pressure hydrocephalus: a revisionist interpretation. (1995) (3)
Choosing a treatment. (2010) (3)
Trends and outcomes associated with gastrostomy tube placement in common neurodegenerative disorders (2020) (3)
Vitamin B12 (cobalamin) and Parkinson’s disease (2012) (3)
Jaw clonus frequency does not support hypothesis of peripheral mechanism of self-re-excitation (2015) (3)
Shortness of breath in Parkinson's disease. (2011) (3)
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings (2006) (3)
Alternating unilateral jaw spasm due to metoclopramide. (1986) (3)
Shared Decision Making or Paternalism? (2016) (2)
Recommendations on the drug treatment of psychosis in Parkinson's disease. (2010) (2)
FUNCTIONAL ABILITY AND FUNCTIONAL CAPACITY IN PATIENTS WITH PARKINSON??S DISEASE (2001) (2)
Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2020) (2)
Medical marijuana in Huntington's disease: report of two cases. (2012) (2)
Dreams in neurological diseases. (2006) (2)
Thoughts on fatigue in Parkinson's disease (and other disorders) (2017) (2)
Treatment of Fatigue in Parkinson’s Disease (2019) (2)
Antidepressants and movement disorders (2015) (2)
Number needed to treat (NNT); number needed to harm (NNH). (2012) (2)
Motor side effects of atypical antipsychotic drugs (2009) (2)
Etiology and overview (2012) (2)
Neuroleptic Malignant Syndrome (1987) (2)
Medication-Induced Movement Disorders (2015) (2)
Reply from the Authors (1990) (2)
Vital signs stable. (1999) (2)
Non-Motor Symptoms and Associated Factors in Parkinson's Disease Patients in Addis Ababa, Ethiopia: A Multicenter Cross-Sectional Study (2021) (2)
Azorean (Machado-Joseph) disease. (1988) (2)
18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson disease. (2002) (2)
Book Review Guide to Clinical Neurology Edited by J.P. Mohr and J.C. Gautier. 1030 pp. New York, Churchill Livingstone, 1995. $85. 0-443-08927-2 (1996) (1)
Comments and Reply on Ikeguchi and Kuroda: Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs (2005) (1)
Racial and geographic disparities with gastrostomy tube placement in dementia and parkinsonian disorders. (2021) (1)
Chief complaint. (2011) (1)
My black bag. (2006) (1)
Active-controlled versus placebo-controlled trials. (1999) (1)
Clozapine Use in a Movement Disorder Clinic (2022) (1)
Brain treatments and creativity. (2014) (1)
When is a somatic disorder psychiatric? (2008) (1)
Paroxysmal dyspnea in Parkinson's disease: Respiratory dyskinesias and autonomic hyperventilation are not the same. (2021) (1)
White Coats. (2017) (1)
Fast Facts: Psychosis in Parkinson's Disease (2019) (1)
Early- vs late-start levodopa relieved symptoms but did not affect disease progression in Parkinson disease (2019) (1)
Absolute Agranulocytosis After 9 Weeks of Clozapine 25 mg Daily. (2022) (1)
The Naranjo Scale and Tardive Syndromes, a Historical Perspective. (2019) (1)
Neuropsychiatric disorders: What do neurologists think about conversion disorder? (2011) (1)
On reviewing manuscripts. (2003) (1)
Prison ethics. (2011) (1)
Normal pressure hydrocephalus. (2004) (1)
Can fall of blood pressure prevent falls in Parkinson disease? (2014) (1)
Current evidence-based guidelines for the management of Parkinson’s disease (2012) (1)
Visual hallucinations in photographs in Parkinson's disease (2013) (1)
Thank God for rich women with mustaches. (2001) (1)
Gait disorders in the elderly. (2012) (1)
Re: Clinical feature profile of spinocerebellar ataxia type 1–8 predicts genetically defined subtypes (2007) (1)
Attention Deficit Hyperactivity Disorders: Animal Models (2014) (1)
M-E-053 EFFECTS OF TRANSDERMAL ROTIGOTINE ON SLEEP AND NOCTURNAL SYMPTOMS OVER A 1-YEAR PERIOD IN PARKINSON'S DISEASE: AN OPEN-LABEL EXTENSION OF THE RECOVER STUDY (2011) (1)
Alpha-synuclein pathology in colonic biopsy of a suspected multiple system atrophy patient - a case report (P1.177) (2015) (1)
The evaluation of the swallow tail sign in patients with parkinsonism and gait disorders (2021) (1)
Advances in Parkinson's Disease Management (2012) (1)
Dystonic Gait Developing After Elective, Unremarkable Hip Surgery. (2016) (1)
Too much of a good thing. (2011) (1)
Recognising hemihypomimia as a mimic of ‘facial weakness’ (2020) (1)
Clozapine treatment of psychosis in patients with Parkinson's disease. (1994) (1)
Psychiatric Aspects of Parkinson’s Disease (2006) (1)
Anti-Parkinson Drugs (2014) (1)
Randomized, double-blind, placebo-controlled trials: the gold standard? (2004) (1)
Chemical imbalance or moral weakness? Personal responsibility in a time of brain science. (2006) (1)
Comment on: Atypical antipsychotics mechanisms of action. Author's reply (2003) (1)
Alien abductions as a risk factor for Parkinson's disease [April Fool]. (2003) (1)
Corrigenda: Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase (2016) (1)
Really dead. (2002) (1)
Editorial and introduction: Behavioral aspects of Parkinson's disease (2017) (1)
Book ReviewMovement Disorders 2 (1987) (1)
Psychiatry/Neurology Pretest Self Assessment and Review (1981) (1)
Clozapine Is Severely Underused in Parkinson's Disease Patients (2022) (1)
A novel promising therapeutic approach for patients with ataxic disorders? (2018) (1)
IRBs and the private office. (2007) (1)
Evaluating Oculomotor Tests before and after Vestibular Rehabilitation in Patients with Parkinson's Disease: A Pilot Pre-Post Study (2022) (1)
Reply: Atypical Antipsychotics Mechanisms of Action (2003) (1)
Specialists and the current medical "system". (2000) (0)
Driving and the physician: a (more) modest proposal. (1999) (0)
"No autopsy--he's suffered enough.". (2002) (0)
Second opinions. (2000) (0)
A Shot to the Gut. (2019) (0)
How can you be two places at once when you're not anywhere at all? (2012) (0)
Who's the criminal? (2000) (0)
The admiral and the General. (2010) (0)
On Time. (2015) (0)
MEDICAL HISTORY (2002) (0)
Non-Paroxysmal Progressive Ataxia in an Adult Due to a Novel Mutation of the CACNA 1 A Gene (2017) (0)
Doctors falling down on the job. (2017) (0)
"Medical marijuana" use in a movement disorders clinic in Rhode Island. (2014) (0)
Letter on Proposals for Gait Research (2022) (0)
Establishing a legacy: the Aronson Chair for Neurodegenerative Disorders. (2013) (0)
Medical etiquette: pro and con. (1999) (0)
Fatigue: A Common Comorbidity in Parkinson’s Disease (2013) (0)
New anti-parkinsonian drugs. (1998) (0)
Doctor's revenge. (2006) (0)
Localizing the wandering uterus. (2010) (0)
Supplements (1992) (0)
Reimbursement for experience-based medicine. (2009) (0)
The Journal of Goldberg Research (April Fool). (2007) (0)
Imaging in medication-induced parkinsonism (2015) (0)
Apathy in Parkinson disease (2020) (0)
Inpatient Mortality in Parkinson’s Disease (2023) (0)
Gamma Knife I ’ allidotomv / in Advanced Parkinson ’ s Disease (2004) (0)
Better than medicine. (2001) (0)
Voting Aliens, Donald Trump and Me. (2017) (0)
Sporadic Parkinsonism-Dementia Complex of Rhode Island with Unusually Abundant Glial TDP-43 Immunoreactivity (2017) (0)
Maprotiline-induced ataxia. (1986) (0)
Self-perception of tremor and dyskinesia (P5.283) (2015) (0)
Announcing a new continuing medical education course: “Bridging Neurology and Psychiatry: Movement Disorders”. (2013) (0)
Rat doctors. (2008) (0)
Controversies in the treatment of Parkinson's disease. (1985) (0)
Combined dopaminergic and nondopaminergic therapies (2012) (0)
Past exposure to neuroleptics is associated with the risk of developing Parkinson's disease (2012) (0)
Apathy in Parkinson's disease: Why we should care. (2020) (0)
The Misperceived Curmudgeon. (2016) (0)
James Parkinson did NOT describe respiratory changes in The Shaking Palsy. (2023) (0)
Acute Onset Parkinsonism in a Middle-Aged Alcoholic: A “Great Case” (2012) (0)
Infected teeth and blind eyes. (2006) (0)
Trojan horse advertising. (1999) (0)
Being solicitous or getting even? (2002) (0)
Parkinson's disease update. (1989) (0)
Tardive Dyskinesia due to Aripiprazole. (2021) (0)
Eponyms: What's in a Name? (2023) (0)
To the Editor (1990) (0)
Neurological novels. (2013) (0)
Are atypical antipsychotics associated with a reduced risk of developing parkinsonism? (2006) (0)
Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field ofClinical Practice (2012) (0)
Rotigotine Transdermal System Improves Pain in Patients with Parkinson's Disease: A Post-Hoc Analysis of Patients Reporting Pain in the RECOVER Study (P06.085) (2012) (0)
Butler Hospital announces the Aronson Chair for Neurodegenerative Disorders. (2014) (0)
CORRECTION (2008) (0)
Introduction to geriatric neurology issue. (2008) (0)
Winning the battle but losing the war: many silver linings are in clouds. (2005) (0)
Gait abnormalities are too hard to evaluate, so why bother? (2005) (0)
Sleep disturbances in Parkinson’s disease: beyond a regional perspective. Time to do something about it (2020) (0)
Demented politicians. (2002) (0)
"The evil among us" or "the buck stops there". (2003) (0)
Estimating the Cumulative Risk of PD in Carriers of Parkin Mutations: The CORE-PD Study (PD4.007) (2012) (0)
Knee lichenification in Parkinson's disease: "Parkinson knees". (2009) (0)
Medical conferences. (2010) (0)
Hanging the crepe. (2010) (0)
A new paradigm for clinical studies? (2011) (0)
Biased articles. (2009) (0)
Clinically Determined Asterixis Is Markedly Increased in Patients Taking Clozapine (2023) (0)
The Not-So-Near Death of Autopsies in the U.S. (2016) (0)
Evidence-based medicine & medical myths. (2000) (0)
Neurology In Primary Care (1998) (0)
My African experiences. (2013) (0)
A Good Partner Makes the Difference What ' s in a Name ? ? ? (2005) (0)
Ignorance is bliss? An ethical question. (2004) (0)
Astasia-abasia as an incidental finding. (2006) (0)
Letters to the editor (0)
Klinefelter's Syndrome with Tremors, Ataxia and Parkinsonism. (2023) (0)
Reporting enrollment in clinical trials. (2002) (0)
Reply (2000) (0)
Book ReviewPrinciples of Neurology (1990) (0)
Movement disorders: resources in Rhode Island. (1993) (0)
Biomarkers of Parkinson’s disease (2012) (0)
'How not to do things' - FDA approval of new Alzheimer's drug triggers controversy. (2021) (0)
My ties to big pharma. (2008) (0)
Development of low weight forgings (1948) (0)
Evolving medicine. (2001) (0)
Short report Preparation of manual movements in hemiparkinsonism (2004) (0)
Negative hallucinations [April Fool's]. (2010) (0)
Getting Wiser, or Just More Crotchety? (2021) (0)
The Good Neighbor Alliance (2008) (0)
Peer review: phony data, shoddy work or revolutionary results? "Truth will out". (2000) (0)
The Effect of Parkin Mutation Status on Cognitive Functioning in EOPD Patients with Long Disease Duration: The CORE-PD Study (PD7.008) (2012) (0)
Cognitive Sinks & the Bermuda Triangle of fMRI Cognitive Studies. (2021) (0)
Short report Tardive dystonia in a psychiatric hospital (0)
The Blue Cross & Blue Shield of RI and Brown University Collaboration (0)
Breaking bad news. (2013) (0)
Recent research advances in Parkinson's disease: Part I. (1986) (0)
The why of neurological reflexes. (2018) (0)
Tardive dystonia inapsychiatric hospital (1987) (0)
The woman who could spell backwards. (2017) (0)
Comment on: Tardive dyskinesia model in the common marmoset (2003) (0)
Introduction to the aging brain, Part 1. (2012) (0)
Retirement: for better or worse? (2014) (0)
Atypical antipsychotics and movement disorders (2015) (0)
A TV moment. (2003) (0)
Increased interleukin 1RA and VCAM 1 in Parkinson patients with fatigue (2017) (0)
Parkinsonian side effects of atypical antipsychotics in the elderly (2005) (0)
On being grandfathered. (2005) (0)
Failing marks in optimism. (2012) (0)
Treating Depression in Parkinson Disease (2009) (0)
Prison clinical trials. (2000) (0)
Subjective Memory Impairment and Subjective Cognitive Improvement: Role for D-C2H5OH (Deuterated Ethyl Alcohol)? Results of a Double-Blind, Crossover Trial. (2020) (0)
Medical errors. (2000) (0)
Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to Clinical Practice (2012) (0)
Managing psychosis in Parkinson’s disease (2011) (0)
Pramipexole for Depression in Parkinson Disease (2010) (0)
Prior authorizations and denials. (2013) (0)
What is an animal model ? (2005) (0)
Sharing bad news. (2006) (0)
Chapter 118 – Mental Changes in Parkinson's Disease (2003) (0)
Chapter 85 – Vascular Disease of the Spinal Cord (2003) (0)
Primary movement disorders. (1990) (0)
Bariatric surgery in Parkinson's disease patients. (2016) (0)
Front & Back Matter (2020) (0)
Knee Lichenification In Parkinson's Disease: (2009) (0)
Evaluation of Phosphodiesterase 10A (PDE10A) Using MNI-659 PET Imaging in Huntington's Disease (P07.212) (2013) (0)
Perspectives on the Art of Scientific and Medical Writing. (2023) (0)
Brain Treatments and Creativity. (2015) (0)
Research proposal to my readers. (2011) (0)
Hoffmann's Sign with Clonus. (2023) (0)
Reflections from the editor-in-chief on 20-year tenure. (2018) (0)
Curing lawyers [April fool's]. (2005) (0)
Talkative patients. (2017) (0)
Acronyms: what's in a name? (2009) (0)
Reply from the authors (0)
Physician overextenders. (2019) (0)
Ethical guidelines and guidelines on ethics are not the same. (2007) (0)
A great case! (2011) (0)
Response to Point of View on the Question of Bias. (2019) (0)
Book targets IRB delays in medical research; proposes a more humane paradigm. (2023) (0)
Culture gaps. (2006) (0)
When the doctor is crazier than the patient. (2017) (0)
An up-front guide to getting promoted: slow and steady. (2014) (0)
Best doctors. (2000) (0)
UNDER THE JOINT EDITORIAL SPONSORSHIP OF (2006) (0)
Magaziner on healthcare reform: lower administrative costs, empower physicians, providers. (2014) (0)
PHYSICAL ACTIVITY, FUNCTION AND FATIGUE IN PARKINSON??S DISEASE. (2003) (0)
Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease (2020) (0)
No stone unturned? (2016) (0)
Cowboy medicine or good clinical judgment? Testing minimalism. (2010) (0)
Restless legs syndrome (2015) (0)
Let sleeping dogs lie. (2014) (0)
Migraine with unilateral mydriasis. (2016) (0)
CHAPTER M1 – Drug-Induced Movement Disorders (2005) (0)
Electronic medical records. (2008) (0)
Repetitive Behavior (2021) (0)
Altruism and my nine gallons of blood. (2013) (0)
Ethics, money & negative studies. (2001) (0)
Medication trials in an imperfect world: gout and Parkinson's disease. (2009) (0)
Sleep deprivation and medicine. (2004) (0)
Treatment-induced mental changes in Parkinson's disease. (2007) (0)
Use of atypical antipsychotics in neurodegenerative diseases (2006) (0)
'Non-physiological' Disorders. (2022) (0)
"I don't do maintenance". (2012) (0)
The way things were, or, in the days of the "giants". (2009) (0)
Medical Passports. (2016) (0)
The Ecology of Neonatology In Rhode Island : Improving Health Care For Newborns (2010) (0)
Thoughts on malpractice. (2013) (0)
Putting on shoes--acts of humility. (2001) (0)
Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al. (2019) (0)
Parochialism and biased reviews. (2011) (0)
April fool's commentary: in praise of placebos. (2006) (0)
Reporting enrollment in clinical trials. Authors' reply (2002) (0)
We can't afford to see patients. (2003) (0)
American Academy of Neurology Practice Parameters: Parkinson Disease Diagnosis and Treatment (2006) (0)
Ten Percent Brain Function: Fact or Fantasy? (2015) (0)
Legal overprotection. (2004) (0)
Checklists: You documented it, but did you do it? (2016) (0)
Interview: Reflections on three decades of clinical practice and clinical research (2014) (0)
COMMENTARIES 360 Astasia-Abasia as an Incidental Finding (2006) (0)
Movement disorders: Neurologic principles and practice. By Ray Watts, MD, and William C. Koller, MD. Ontario, Canada: McGraw‐Hill Ryerson Ltd, 1997, 832 pp., 400 illustrations. Price: $181.25 Canadian. ISBN 0‐07‐035203‐8 (1998) (0)
YAWNING IN PARKINSON'S DISEASE. AUTHORS' REPLY (1999) (0)
Management of cognitive and behavioral aspects of Parkinson's disease (2013) (0)
A good result isn't always a good result. (2007) (0)
National Parkinson Foundation Hospitalization Survey (2014) (0)
Parkinson disease. (1987) (0)
Bloodletting in the 21st Century? (2016) (0)
Institutional Review Board (IRB) Overreach. (2022) (0)
Atypical Parkinsonian syndromes with very poor striatal uptake on 123I-ioflupane SPECT imaging. (2015) (0)
Joe's prior auth service. (2013) (0)
Needless tests. (2002) (0)
Three A's or four; or, what do patients want in a doctor? (2010) (0)
Missed opportunities, missing opportunities and clinical creativity. (2005) (0)
Upper and (old) lower facial (VII) nerve palsies on opposite sides. (2009) (0)
Personalized Medicine: Is it a concept only for the super-rich? (2015) (0)
Centennial Thoughts. (2017) (0)
Apps replies (1986) (0)
Dress codes for doctors. (2007) (0)
Why don't doctors return phone calls? (2021) (0)
Thanks for the bad news. (2006) (0)
Looking good, feeling bad, the Marilyn Monroe syndrome. (2001) (0)
Brain waves and the era of cosmetic neurology. (2011) (0)
Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
Acute Parkinsonism 9 9 (2017) (0)
MCI in Parkinson's disease. (2018) (0)
Management of psychotic symptoms in Parkinson’s disease (2012) (0)
Voter restrictions in Florida (and elsewhere in the United States). (2012) (0)
Ebola vaccine and corporate responsibility. (2015) (0)
Psychosis in Parkinson's Disease (2011) (0)
Medical Notes (1896) (0)
Vitamin D deficiency and falls (2011) (0)
Aiming low: advice to residents considering a research project. (2014) (0)
Commentary on "The Neuropsychiatry of Parkinson's Disease: A Perfect Storm". (2019) (0)
Secondary torticollis (1992) (0)
Yawning, or not having enough to do. (2012) (0)
Doctors vs. doctors. (2004) (0)
Treating Agitation in Alzheimer Disease (2007) (0)
Corrigenda: Eldad Melamed 1942–2015: Ave atque–A memorial (2016) (0)
On choosing one's patients. (2003) (0)
Recent research advances in Parkinson's disease: Part II. Studies in lower animals indicate a future for brain implants. (1986) (0)
Neurology requirements at Brown. (2009) (0)
Task Specific Tremors. (2015) (0)
Thinking too much is bad for some brains. (2018) (0)
Programming andexecution ofsequential movements inParkinson's disease (1987) (0)
Feudalism or futilism: another modest proposal. (2007) (0)
Talking About Patients in Front of Them. (2015) (0)
Graybeards, or grayheads. (2007) (0)
Where quality is job one? (2003) (0)
How much is it worth? (2012) (0)
Where Are the Words To Heal ? (2003) (0)
NPH on TV. (2005) (0)
Muscarinic Cholinergic Receptor Agonists and Antagonists (2015) (0)
Brain cramps. (2002) (0)
Acute Onset of Akinetic Mutism With Rigidity in an Elderly Psychiatric Patient: A Reminder on Catatonia (2012) (0)
EBM: evidence-based medicine or experience-based medicine? (2011) (0)
Anticholinergics in dementia and other confounding problems. (2006) (0)
Nondystonic torticollis (1993) (0)
Needless tests. (2002) (0)
RHINORRHEA AND OLFACTION IN PARKINSON DISEASE. Authors' reply (2008) (0)
Feeling comfortable with not knowing. (2003) (0)
Non-motor movement disorders: internal tremor. (2009) (0)
Cell and gene transplantation for Parkinson’s disease: view from the clinic (2012) (0)
Anticholinergics in dementia and other confounding problems. Author's reply (2006) (0)
First do no harm--unless.... (2003) (0)
Brain warfare: primates to humans? (2014) (0)
Evidence-based Medicine. (2018) (0)
Quetiapineof its Clinical Potential in the Management of Psychotic Symptoms in Parkinson's Disease (2000) (0)
Every silver lining has a cloud. (2005) (0)
Parkinson, Shaking Palsy MS#1817-010038. reviewer comments [April fools]. (2012) (0)
My Newest Favorite Hallucination. (2021) (0)
Recognizing dementia with Lewy bodies in older people (2010) (0)
Making the Connection Between Brain and Behavior: Coping with Parkinson's Disease (2007) (0)
Neuroleptic Malignant Syndrome-Reply (1986) (0)
What to do when bad news isn't understood? (2018) (0)
Jaundiced eye. (2014) (0)
Drug therapies for neuropsychiatric and autonomic disturbances in patients with PD (2012) (0)
Simplicity isn't always a virtue. (2014) (0)
Small research. (2014) (0)
Reply (1999) (0)
Doctor seer. (2005) (0)
Response to Letter to the Editor (2019) (0)
The Four Humors (Updated for Neurologists). (2023) (0)
Continuing medical education (CME): goals and objectives. (2010) (0)
Presence Hallucinations" in PD Patients. (2020) (0)
Superaging, the new phrenology, and the gluten-free diet for the brain. (2017) (0)
Further Thoughts on Antipsychotics in Dementia with Lewy Bodies (2017) (0)
Standard of Care. (2016) (0)
An April Fool's Day commentary. What a difference a scale makes! (2002) (0)
Memory feats. (2014) (0)
Some thoughts on ethical guidelines for the neurologically-impaired elderly. (2008) (0)
Psychogenic disorders: the consultants' responsibility, or "rule out" doctors. (2004) (0)
Common sense. (2007) (0)
Cognitive behavioral therapy for psychogenic movement disorder (0)
CATS: a new answer to an old problem. (2008) (0)
Personalized Medicine in the Resource-poor World. (2016) (0)
"... But I can still sue you, can't I"? (2007) (0)
Old Age , Stricken in Years (2005) (0)
Anger in Patients with Parkinson Disease (2008) (0)
The academic--corporate interface in medicine. (2000) (0)
Do quality of life measures measure anything we want to measure? (2008) (0)
Neuroprotective trials: no longer a cautious optimism. (2008) (0)
Laughing at patients. (2013) (0)
Getting older. (2011) (0)
Why people in RI won't drive far: a scientific explanation. (2009) (0)
'Goodbye, and thanks…'. (2018) (0)
Disorders without explanation. (2014) (0)
End-of-life discussions. (2015) (0)
Zambian dilemma, American solution. (2004) (0)
Publish (if you can). (2014) (0)
Warning on treating depression. (2010) (0)
What kind of doctor am I? (2012) (0)
First annual April (fool's) commentary. Cognitive sinks: the black holes of neuropsychology: a brief overview. (2000) (0)
What does it mean for a treatment to 'work?'. (2013) (0)
Neurological stigma. (2013) (0)
Iatrogenesis imperfecta. (2002) (0)
Response to Letter to the Editor (2010) (0)
The surgeon general: why not have one? (2005) (0)
Self-perception and insight. (2014) (0)
Break point. (2016) (0)
At 10 years, 55% of patients with Parkinson disease died; 23% had a good outcome (2013) (0)
Quackery in the incurable. (2001) (0)
Into the Ether. (2016) (0)
Political correctness is unethical. (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joseph Harold Friedman?

Joseph Harold Friedman is affiliated with the following schools:

Brown University